Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

Key Points

• Director Ken Takanashi sold 3,864 WAVE Life Sciences shares at an average price of $6.01, totaling $23,222.64. The sale covered tax-withholding obligations tied to vested equity awards and reduced his direct holdings by 16.14%.
• WAVE shares traded at $5.20, near their 12-month low of $5.01, after the company reported a quarterly loss of $0.34 per share and revenue of $2.27 million—both worse than analysts’ expectations.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and a $22.53 average price target, while institutional investors own approximately 89.73% of the company.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) Director Ken Takanashi sold 3,864 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total value of $23,222.64. Following the completion of the sale, the director directly owned 20,079 shares of the company's stock, valued at approximately $120,674.79. This represents a 16.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

WAVE Life Sciences Trading Down 0.8%

Shares of WVE stock traded down $0.04 during trading hours on Thursday, hitting $5.20. 6,048,504 shares of the company's stock were exchanged, compared to its average volume of 2,757,944. The company has a market capitalization of $1.02 billion, a PE ratio of -4.77 and a beta of -1.26. WAVE Life Sciences Ltd. has a 12-month low of $5.01 and a 12-month high of $21.73. The business's 50 day simple moving average is $5.88 and its 200-day simple moving average is $8.42.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%.The business had revenue of $2.27 million during the quarter, compared to the consensus estimate of $7.45 million. Equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.12 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating on shares of WAVE Life Sciences in a report on Monday, August 3rd. Citigroup reduced their price target on WAVE Life Sciences from $24.00 to $19.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Wedbush lowered their price objective on WAVE Life Sciences from $15.00 to $12.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Truist Financial initiated coverage on WAVE Life Sciences in a research note on Wednesday, April 29th. They set a "buy" rating and a $15.00 price objective for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of WAVE Life Sciences in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, WAVE Life Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $22.53.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of WVE. GSK plc purchased a new stake in WAVE Life Sciences in the 4th quarter worth approximately $310,177,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock valued at $97,607,000 after acquiring an additional 2,500,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in WAVE Life Sciences by 83.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company's stock worth $125,927,000 after acquiring an additional 3,362,880 shares during the period. Darwin Global Management Ltd. purchased a new stake in WAVE Life Sciences in the fourth quarter worth $125,168,000. Finally, Federated Hermes Inc. boosted its holdings in WAVE Life Sciences by 26.5% in the fourth quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company's stock valued at $80,657,000 after acquiring an additional 993,827 shares in the last quarter. Institutional investors own 89.73% of the company's stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source